If the author’s manuscript is assessed as inappropriate to be published in his/her preferred journal, our editorial team may help the author in transferring the submission to a more appropriate Bentham Journal, through Bentham’s Manuscript Transfer Facility.
Transfer of Submission
Transfer of submission with Bentham’s Manuscript Transfer Facility is very simple.
The Author receives the transfer proposal by email - the transfer process is initiated by an affirmative response from the author to our transfer proposal.
The Authors’ manuscript is transferred to a suitable journal for initial editorial scrutiny.
The Author then receives an editorial decision from the journal.
Selection of another Journal
The Author is free to choose to submit the manuscript to a new journal by declining our transfer offer.
Our aim is to facilitate and develop rapid, effective and truly innovative solutions to facilitate our valued authors by enabling more options and better services to improve the publication process.
Vladimir P. Torchilin (68301 citations) Center for Pharmaceutical Biotechnology and Nanomedicine Northeastern University Boston, Massachusetts (United States) Biography
Biography of Vladimir P. Torchilin
Vladimir P. Torchilin, Ph.D., D.Sc. is a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. His interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. He has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar has shown more than 44,000 citations of his papers with an H-index of 96. He is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. He received more than $30 M from the governmental and industrial sources in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among the top world scientists in pharmacology for the period of 2000-2010.